Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2001-09-30
2009-11-10
Nickol, Gary B. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S189100, C424S184100, C530S350000, C435S005000, C435S069300
Reexamination Certificate
active
07615228
ABSTRACT:
A purified polypeptide comprising the amino acid sequence as set forth in SEQ ID No. 1 of hepatitis E virus ORF 2 or its fragment, which is in the form of a polymer with n monomeric polypeptides, wherein n is an integer from 2-180; to a polypeptide of the present invention bound to a polypeptide containing epitope from hepatitis E virus ORF3or an immunogenic fragment thereof; to a recombinant expression vector comprising the DNA molecule encoding the above polypeptides and the host cell transformed with said recombinant expression vector which is able to express polypeptide of the present invention. The present invention further relates to a vaccine composition against hepatitis E virus which comprises the above-mentioned polypeptide, or diagnostic kit for hepatitis E virus infection comprising the above-mentioned polypeptide, which includes IgG, IgM, or total antibody diagnostic kit for hepatitis E virus, and to the use of vaccine composition and diagnostic kit for prophylaxis, diagnosis and/or treatment of hepatitis E virus infection.
REFERENCES:
patent: 6054567 (2000-04-01), Emerson et al.
patent: WO 9517501 (1995-06-01), None
patent: PCT/US95/13102 (1995-11-01), None
patent: WO 9612807 (1996-05-01), None
patent: WO 0122916 (2001-04-01), None
Li et al (1992) J of Virology. 66(1):399-404.
Muster et al (1994) J of Virology. 68(6): 4031-4034.
Favorov et al (1996) Journal of Medical Virology. 50: 50-58.
Emerson and Purcell. Trends Mol Med. Oct. 2001;7(10):462-6. Review.
Li, F. et al.: “Recombinant Subunit Orf2.1 Antigen and Introduction of Antibody Against Immunodominant Epitopes in the Hepatitis E Virus Capsid Protein” Journal of Medical Virology, New York, NY, US, Apr. 2000.
Riddell, M. A. et al.: “Identification of Immunodominant and Conformational Epitopes in the Capsid Protein of Hepatitis E Virus by Using Monoclonal Antibodies” Journal of Virology, United States, Sep. 14, 2000.
Li, T-C et al.: “Expression and Self-Assembly of Empty Virus-Like-Particles of Hepatitis E Virus” Journal of virology, United States, Oct. 1, 1997.
Xing, L. et al.: “Recombinant Hepatitis E Capsid Protein Self-Assembles into a Dual-Domain T=1 Particle Presenting Native Virus Epitopes” Virology, Academic Press, Orlando, US, Dec. 5, 1999.
Anderson, D. A. et al.: “Elisa for IGG-Class Antibody to Hepatitis E Virus Based on a Highlyconserved, Conformational Epitope Expressed inEscherichia coli” Journal of Virological Methods, Amsterdam, NL, Aug. 1999.
Zhang, J-Z et al.: “Conformational Antigenic Determinants Generated by Interactions Between a Bacterially Expressed Recombinant Peptide of the Hepatitis E Structural Protein” Journal of Medical Virology, Alan R. Liss, New York, NY, US, Jun. 2001.
Ge Shengxiang
Gu Ying
He Zhiqiang
Li Shaowei
Xia Ningshao
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Horning Michelle
Ladas & Parry LLP
Nickol Gary B.
LandOfFree
Polypeptide fragments of hepatitis E virus, the vaccine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polypeptide fragments of hepatitis E virus, the vaccine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polypeptide fragments of hepatitis E virus, the vaccine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4102870